DSCO Share Price

Open 3.86 Change Price %
High 3.86 1 Day -0.36 -9.33
Low 3.50 1 Week 0.00 0.00
Close 3.50 1 Month 0.00 0.00
Volume 291893 1 Year 3.25 1300.00
52 Week High 3.93
52 Week Low 0.00
DSCO Important Levels
Resistance 2 3.83
Resistance 1 3.70
Pivot 3.62
Support 1 3.30
Support 2 3.17
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Discovery Laboratories, Inc. (NASDAQ: DSCO)

DSCO Technical Analysis 5
As on 18th Apr 2016 DSCO Share Price closed @ 3.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.89 & Strong Buy for SHORT-TERM with Stoploss of 2.15 we also expect STOCK to react on Following IMPORTANT LEVELS.
DSCO Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DSCO Other Details
Segment EQ
Market Capital 101651808.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.discoverylabs.com
DSCO Address
DSCO
2600 Kelly Road
Suite 100
Warrington, PA 18976
United States
Phone: 215-488-9300
DSCO Latest News
Interactive Technical Analysis Chart Discovery Laboratories, Inc. ( DSCO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Discovery Laboratories, Inc.
DSCO Business Profile
Discovery Laboratories, Inc. is a biotechnology company focused on creating life-saving products for critical care patients with respiratory disease. The Company�s produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. In addition, its capillary aerosol-generating technology produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 surfactant to the lung. It is developing its products, Surfaxin(lucinactant), Surfaxin LS and Aerosurf, to address the respiratory conditions affecting neonatal populations. It has filed a New Drug Application (NDA) for its product based on its KL4 surfactant technology, Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. It focuses on manufacturing three additional Surfaxin batches for use in the preclinical program.